This is a low-impact, non-binding exploratory collaboration announcement with no financial terms. Monitor for future definitive agreements or clinical evidence readouts that could validate expanded use of Telix's imaging agents. The insider buying is a modest positive but does not change the near-term outlook.
Price Chart
Executive Summary
Telix announced non-binding letters of intent to collaborate with EDAP TMS and Profound Medical, exploring the use of its PSMA-PET imaging agents (Gozellix and Illuccix) with robotic HIFU and TULSA ablation platforms for prostate cancer. The collaborations are early-stage, focused on scientific and educational research, with no financial terms disclosed and no immediate revenue impact.
Key Facts
- Telix entered letters of intent with EDAP TMS (Focal One robotic HIFU) and Profound Medical (TULSA-PRO MRI-guided ablation) for prostate cancer.
- Collaborations focus on investigational use of PSMA-PET imaging agents Gozellix and Illuccix for patient selection, treatment planning, and post-treatment monitoring.
- No financial terms, milestones, or revenue commitments were disclosed.
- PSMA-PET imaging is not currently approved for the specific treatment-planning indications explored in these collaborations.
- Telix's market cap is ~$3.7B; insider buying of ~$997K in the prior 30 days provides a modest positive signal.
Financial Impact
No financial terms disclosed; collaborations are non-binding and exploratory.
Risk Factors
- Collaborations are non-binding letters of intent — may not result in definitive agreements.
- PSMA-PET imaging is not yet approved for the specific treatment-planning indications explored.
- No revenue or financial impact expected in the near term.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295677 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $12.83 $11.95 | ▼ −6.86% | ▼ −8.99% | $10.55 (−17.77%) |
Sep 14, 2026 18d ago | Press Release | $11.78 $11.31 | ▼ −3.99% | ▼ −4.10% | $10.55 (−10.44%) |
Sep 2, 2026 4w ago | 6-K | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Sep 1, 2026 4w ago | Press Release | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Aug 20, 2026 6w ago | 6-K | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Aug 20, 2026 6w ago | Press Release | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Jul 30, 2026 9w ago | Press Release | $9.89 $11.52 | ▲ +16.48% | ▲ +12.97% | $10.55 (+6.67%) |
Jul 21, 2026 10w ago | Press Release | $10.32 $10.10 | ▼ −2.13% | ▲ +0.27% | $10.55 (+2.23%) |
Jul 21, 2026 10w ago | 6-K | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
Jul 20, 2026 10w ago | Press Release | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access